دورية أكاديمية
أعرض في EDS

The prevalence and risk factors for cognitive impairment in obesity and NAFLD.

التفاصيل البيبلوغرافية
العنوان: The prevalence and risk factors for cognitive impairment in obesity and NAFLD.
المؤلفون: Wernberg CW; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of Southern Denmark, Esbjerg, Denmark.; Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark., Grønkjær LL; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of Southern Denmark, Esbjerg, Denmark., Gade Jacobsen B; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of Southern Denmark, Esbjerg, Denmark., Indira Chandran V; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Krag A; Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, Denmark., Graversen JH; Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Weissenborn K; Department of Neurology, Medical School, Hannover, Hannover, Germany., Vilstrup H; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Lauridsen MM; Department of Gastroenterology and Hepatology, Liver Research Group, University Hospital of Southern Denmark, Esbjerg, Denmark.
المصدر: Hepatology communications [Hepatol Commun] 2023 Jun 28; Vol. 7 (7). Date of Electronic Publication: 2023 Jun 28 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc.
Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc. on behalf of the American Association for the Study of Liver Diseases, [2017]-
مواضيع طبية MeSH: Non-alcoholic Fatty Liver Disease*/complications , Non-alcoholic Fatty Liver Disease*/epidemiology , Non-alcoholic Fatty Liver Disease*/pathology , Cognitive Dysfunction*/epidemiology, Humans ; Male ; Female ; Adult ; Middle Aged ; Prevalence ; Cross-Sectional Studies ; Risk Factors ; Obesity/complications ; Obesity/epidemiology
مستخلص: Background: Severe obesity may be accompanied by cognitive dysfunction and NAFLD, but the associations remain unclear. We describe the prevalence and features of cognitive dysfunction and examine the associations between cognitive dysfunction and the presence and severity of NAFLD, and the associations between cognitive dysfunction and signs of other obesity-related comorbidities and neuronal damage.
Methods: A cross-sectional study of patients with a body mass index of 35 kg/m2 underwent evaluation for bariatric surgery. They were screened for adiposity-related comorbidity and underwent a liver biopsy and basic cognitive testing with the Continuous Reaction Time test, the Portosystemic Encephalopathy Syndrome test, and the Stroop Test. A representative subgroup also underwent the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The primary study outcome was "cognitive impairment," defined as ≥2 abnormal basic cognitive tests and/or an abnormal RBANS. The Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) served as a biomarker for neuronal damage.
Results: We included 180 patients; 72% were women, age 46 ± 12 years, 78% had NAFLD, and 30% with NASH without cirrhosis. 8% were cognitively impaired by the basic tests and 41% by RBANS results. Most impaired were executive and short-time memory functions. There were no associations between cognitive impairment and BMI, NAFLD presence or severity, or metabolic comorbidities. Male sex (OR: 3.67, 95% CI, 1.32-10.27) and using 2 or more psychoactive medications (5.24, 95% CI, 1.34-20.4) were associated with impairment. TREM2 was not associated with cognitive impairment.
Conclusions: Nearly half of this severely obese study cohort exhibited measurable multidomain cognitive impairment. This was not dependent on NAFLD or another adiposity comorbidity.
(Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
التعليقات: Comment in: Hepatol Commun. 2023 Oct 18;7(11):. (PMID: 37902471)
Comment in: Hepatol Commun. 2023 Oct 31;7(11):. (PMID: 37902509)
References: George ES, Sood S, Daly RM, Tan SY. Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review. BMC Geriatr. 2022;22:47.
Shang Y, Widman L, Hagström H. Nonalcoholic fatty liver disease and risk of dementia. Neurology. 2022;99:e574–82.
Xiao T, van Kleef L, Ikram MK, De Knegt R, Ikram MA. Association of nonalcoholic fatty liver disease and fibrosis with incident dementia and cognition: The Rotterdam Study. Neurology . 2022;99:e565–73.
Colognesi M, Gabbia D, De Martin S. Depression and cognitive impairment-extrahepatic manifestations of NAFLD and NASH. Biomedicines. 2020;8:229.
Kjærgaard K, Mikkelsen ACD, Wernberg CW, et al. Cognitive dysfunction in non-alcoholic fatty liver disease—current knowledge, mechanisms and perspectives. J Clin Med. 2021;10:673.
Jericó I, Vicuña-Urriza J, Blanco-Luquin I, et al. Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain Behav Immun. 2023;109:117–26.
Zhang C, Chen S. Role of TREM2 in the development of neurodegenerative diseases after traumatic brain injury. Mol Neurobiol. 2023;60:342–54.
Tsai H-H, Chen Y-F, Yen R-F, et al. Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau. Brain. 2021;144:3371–80.
Li RY, Qin Q, Yang HC, et al. TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Mol Neurodegener. 2022;17:40.
Morenas-Rodríguez E, Li Y, Nuscher B, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer’s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329–41.
McKee CG, Hoffos M, Vecchiarelli HA, Tremblay M. Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease. Front Pharmacol. 2023;14:1125982.
Wang S, Mustafa M, Yuede CM, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217:e20200785.
Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009;29:629–35.
Lauridsen MM, Thiele M, Kimer N, Vilstrup H. The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy. Metab Brain Dis. 2013;28:231–4.
Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol. 2001;34:768–73.
Scarpina F, Tagini S. The Stroop Color and Word Test. Front Psychol. 2017;8:557.
Allampati S, Duarte-Rojo A, Thacker LR, et al. Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: A multicenter US-based, norm-based study. Am J Gastroenterol. 2016;111:78–86.
Karantzoulis S, Novitski J, Gold M, Randolph C. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in Detection and Characterization of Mild Cognitive Impairment due to Alzheimer’s Disease. Arch Clin Neuropsychol. 2013;28:837–44. 10.1093/arclin/act057. (PMID: 10.1093/arclin/act057)
Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Network NCR Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology (Baltimore, Md). 2011;53:810–20.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. 2001;66:159–64.
Levine DA, Gross AL, Briceño EM, et al. Sex differences in cognitive decline among US adults. JAMA Network Open. 2021;4:e210169.
van Zutphen EM, Rijnhart JJM, Rhebergen D, et al. Do Cardiovascular Risk Factors and Cardiovascular Disease Explain Sex Differences in Cognitive Functioning in Old Age? J Alzheimers Dis. 2021;80:1643–55.
Roman G, Rusu A, Graur M, et al. Dietary patterns and their association with obesity: A cross-sectional study. Acta Endocrinol (Buchar). 2019;5:86–95.
Jin U, Park SJ, Park SM. Cholesterol metabolism in the brain and its association with Parkinson’s disease. Exp Neurobiol. 2019;28:554–67.
Eden Friedman Y, Steinberg DM, Canetti M, Cohen I, Segev S, Salomon O. An impact of lipid profile and lipid lowering drugs on ≥70 year olds of an upper socioeconomic class: a retrospective cohort study. Lipids Health Dis. 2021;20:120.
Jurcau A, Simion A. Cognition, statins, and cholesterol in elderly ischemic stroke patients: A neurologist’s perspective. Medicina (Kaunas). 2021;57:616.
Indira Chandran V, Wernberg CW, Lauridsen MM, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness. Hepatology. 2022;77:558–72.
de Paula GC, Brunetta HS, Engel DF, et al. Hippocampal function is fmpaired by a short-term high-fat diet in mice: Increased blood-brain barrier permeability and neuroinflammation as triggering events. Front Neurosci. 2021;15:734158.
Morandini HAE, Watson P, Stewart RM, Wong JWY, Rao P, Zepf FD. Implication of saturated fats in the aetiology of childhood attention deficit/hyperactivity disorder—a narrative review. Clin Nutr ESPEN. 2022;52:78–85.
Kittel-Schneider S, Arteaga-Henriquez G, Vasquez AA, et al. Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity? Neurosci Biobehav Rev. 2022;132:1157–80.
Winterdahl M, Abbas Z, Noer O, et al. Cerebral water content mapping in cirrhosis patients with and without manifest HE. Metab Brain Dis. 2019;34:1071–6.
Anwar N, Tucker WJ, Puzziferri N, et al. Cognition and brain oxygen metabolism improves after bariatric surgery-induced weight loss: A pilot study. Front Endocrinol (Lausanne). 2022;13:954127.
تواريخ الأحداث: Date Created: 20230628 Date Completed: 20230630 Latest Revision: 20231108
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10309508
DOI: 10.1097/HC9.0000000000000203
PMID: 37378627
قاعدة البيانات: MEDLINE
الوصف
تدمد:2471-254X
DOI:10.1097/HC9.0000000000000203